Edgestream Partners L.P. bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 136,187 shares of the biopharmaceutical company’s stock, valued at approximately $4,528,000.
Several other hedge funds also recently made changes to their positions in AGIO. Nykredit A S bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $26,000. Three Bridge Wealth Advisors LLC purchased a new stake in Agios Pharmaceuticals during the 3rd quarter valued at $27,000. Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals in the 2nd quarter worth $43,000. Integrated Wealth Concepts LLC bought a new stake in Agios Pharmaceuticals in the 2nd quarter worth $47,000. Finally, Allworth Financial LP bought a new stake in Agios Pharmaceuticals in the 2nd quarter worth $73,000.
Analyst Ratings Changes
Several brokerages have recently commented on AGIO. Bank of America upped their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Truist Financial reduced their price target on Agios Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, November 6th. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings lowered Agios Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.12.
Read Our Latest Analysis on Agios Pharmaceuticals
Insider Buying and Selling at Agios Pharmaceuticals
In other news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction on Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the sale, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $2,059,570.05. This represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 9,855 shares of company stock valued at $371,112. Corporate insiders own 5.40% of the company’s stock.
Agios Pharmaceuticals Stock Down 3.1%
NASDAQ:AGIO opened at $28.76 on Friday. The stock has a market cap of $1.72 billion, a P/E ratio of -4.55 and a beta of 0.66. The firm’s fifty day simple moving average is $32.76 and its 200 day simple moving average is $31.88. Agios Pharmaceuticals, Inc. has a twelve month low of $23.00 and a twelve month high of $44.09.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.15. Agios Pharmaceuticals had a negative net margin of 264.76% and a negative return on equity of 34.63%. The business had revenue of $55.39 million for the quarter, compared to the consensus estimate of $51.65 million. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -5.72 EPS for the current fiscal year.
About Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.
Recommended Stories
- Five stocks we like better than Agios Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
